home / stock / howl / howl quote
Last: | $2.61 |
---|---|
Change Percent: | 0.69% |
Open: | $2.86 |
Close: | $2.61 |
High: | $2.9864 |
Low: | $2.605 |
Volume: | 386,527 |
Last Trade Date Time: | 06/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.61 | $2.86 | $2.61 | $2.9864 | $2.605 | 386,527 | 06-24-2024 |
$2.88 | $2.79 | $2.88 | $3.035 | $2.7 | 334,033 | 06-21-2024 |
$2.69 | $2.9 | $2.69 | $2.985 | $2.61 | 321,821 | 06-20-2024 |
$2.89 | $3.11 | $2.89 | $3.2 | $2.875 | 230,584 | 06-19-2024 |
$2.89 | $3.11 | $2.89 | $3.2 | $2.875 | 230,584 | 06-18-2024 |
$3.13 | $3.05 | $3.13 | $3.22 | $2.96 | 219,288 | 06-17-2024 |
$3.01 | $3.27 | $3.01 | $3.27 | $3.01 | 193,562 | 06-14-2024 |
$3.25 | $3.15 | $3.25 | $3.49 | $3.135 | 294,835 | 06-13-2024 |
$3.07 | $3.21 | $3.07 | $3.46 | $2.95 | 368,920 | 06-12-2024 |
$3.2 | $3.27 | $3.2 | $3.34 | $3.02 | 171,294 | 06-11-2024 |
$3.25 | $3.18 | $3.25 | $3.47 | $3.06 | 312,672 | 06-10-2024 |
$3.49 | $3.49 | $3.49 | $3.695 | $3.3606 | 172,619 | 06-07-2024 |
$3.5 | $3.59 | $3.5 | $3.645 | $3.35 | 260,315 | 06-06-2024 |
$3.59 | $3.64 | $3.59 | $3.715 | $3.42 | 187,000 | 06-05-2024 |
$3.64 | $4.16 | $3.64 | $4.16 | $3.59 | 297,651 | 06-04-2024 |
$3.99 | $4.73 | $3.99 | $4.73 | $3.89 | 417,262 | 06-03-2024 |
$5.17 | $5.38 | $5.17 | $5.73 | $5.08 | 311,879 | 05-31-2024 |
$5.36 | $5.04 | $5.36 | $5.47 | $4.97 | 110,270 | 05-30-2024 |
$5.09 | $4.87 | $5.09 | $5.21 | $4.87 | 73,390 | 05-29-2024 |
$4.96 | $4.91 | $4.96 | $5.19 | $4.665 | 225,536 | 05-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Werewolf Therapeutics Inc. Company Name:
HOWL Stock Symbol:
NASDAQ Market:
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete respon...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - - Preliminary data on WTX-124 administered in combination with pembrolizumab show similar t...